Peptide-based platform marks a major step toward needle-free diabetes care

For more than a century, oral insulin has been considered a “dream” therapy for diabetes, hindered by enzymatic degradation in the digestive tract and the absence of a dedicated intestinal transport mechanism. Consequently, many patients must rely on daily insulin injections, which can significantly reduce their quality of life.